780800-85-3

Usage

Uses

Used in Organic Synthesis:
5-Phenylpyridine-2-carbaldehyde is utilized as a key intermediate in organic synthesis for the production of a range of chemical compounds. Its unique structure allows it to serve as a building block for the creation of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 5-Phenylpyridine-2-carbaldehyde is employed as a reagent for the preparation of various drugs. Its versatility in chemical reactions makes it a valuable component in the synthesis of new medicinal compounds.
Used in Agrochemical Industry:
5-Phenylpyridine-2-carbaldehyde also finds application in the agrochemical industry, where it is used in the synthesis of pesticides and other agricultural chemicals. Its ability to form stable compounds makes it suitable for developing effective and long-lasting agrochemical products.
Used in Dye Industry:
5-PHENYLPYRIDINE-2-CARBALDEHYDE is used as a precursor in the dye industry for the production of various dyes. Its aromatic nature and reactivity contribute to the development of dyes with specific color properties and stability.
Used in Biological Research:
5-Phenylpyridine-2-carbaldehyde has been investigated for its potential biological activities, such as antimicrobial, antifungal, and antitumor properties. Its ability to interact with biological systems makes it a promising candidate for the development of new therapeutic agents.
Used in Analytical Chemistry:
In the field of analytical chemistry, 5-phenylpyridine-2-carbaldehyde has been used in the development of fluorescent sensors and probes for detecting various metal ions and other analytes. Its fluorescent properties allow for sensitive and selective detection methods in analytical applications.

Upstream product

• 3256-88-0 5-phenyl-2-picoline 
• 86574-52-9 methyl 5-phenylpyridine-2-carboxylate 
• 75754-04-0 5-phenyl-pyridine-2-carboxylic acid 
• 75753-93-4 2-(furan-2-yl)-5-phenylpyridine 
• 121-46-0 bicyclo[2.2.1]hepta-2,5-diene 
• 197847-89-5 (5-phenyl-pyridin-2-yl)-methanol 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 98-80-6 phenylboronic acid 

Downstream Products

• 892502-02-2 N-methyl-1-(5-phenylpyridin-2-yl)methanamine 
• 1610596-31-0 2-methyl-1,4-bis(5-phenylpyridin-2-yl)butane-1,4-dione 

Relevant academic research and scientific papers

Synthesis, photophysical properties and DFT studies of the pyridine-imidazole (PyIm) Cu(I) complexes: Impact of the pyridine ring functionalized by different substituents

A series of the pyridine-imidazole (PyIm) Cu(I) complexes with different substituents (bromide (P1), methyl (P2), and phenyl (P3)) attached on the pyridine ring are synthesized and characterized. All the complexes show the typical metal-to-ligand charge transfer (MLCT) absorption in the visible region. Complex P1 with an electron-withdrawing substituent on the pyridine ring, e.g., a bromine group, shows a red shift of the emission wavelength. Conversely, an electron-donating substituent on the pyridine ring in complex P2, e.g., a methyl group, shifts the emission to longer wavelength. Similarly, complex P3 containing the extended π-conjugation system of the ligand also exhibits a red shift of the emission wavelength. All of the complexes exhibit efficient green-yellow emission in PMMA films at room temperature with emission wavelength of 547–569 nm and quantum yields of 24.8–53.0%. Meanwhile, DFT and TDDFT methods were employed to explain the photophysical properties.

Orange-red emissive Cu(I) complexes bearing Schiff base ligands: Synthesis, structures, and photophysical properties

Herein, the three novel copper (I) complexes bearing Schiff base ligands of the types [Cu(Phen-PyMethylene-Adam-Amine)(POP)]PF6 (P1), [Cu(Methoxyl-Phen-PyMethylene-Adam-Amine)(POP)]PF6 (P2), and [Cu(TriflMethyl-Phen-PyMethylene-Adam-Amine)(POP)]PF6 (P3) (Phen-PyMethylene-Adam-Amine = ((5-phenylpyridin-2-yl)methylene)adamantan-1-amie, Methoxyl-Phen-PyMethylene-Adam-Amine = ((5-(4-methoxyphenyl)pyridin-2-yl)methylene)adamantan-1-amine, TriflMethyl-Phen-PyMethylene-Adam-Amine = ((5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)methylene)adamantan-1-amine, POP=bis[2-diphenylphosphino]-phenyl)ether) have been prepared and investigated. Incorporation of the bulky adamantyl group into the complexes can enhance the stability of the complexes. The different electron-donating/withdrawing groups such as –H, –OCH3, and –CF3 substituents were functionalized onto the pyridine ring part of Schiff base ligands to tune the emission behavior of the resulting Schiff base Cu(I) complexes. All complexes exhibit the lowest energy metal-to-ligand charge transfer (MLCT) characters in 400–450 nm region showing a slight blue-shift of the absorption wavelengths in the order P3 > P1 > P2. Organe-red emissions in the region of 611-619 nm with photoluminescence quantum yields (PLQY) of 1.0–1.3% can be observed in the solid state. Additionally, the photophysical properties are also investigated theoretically using density functional theory (DFT) and time dependent DFT.

1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl, or R1b and R1c together form an optionally substituted C3-C6 cycloalkyl ring, or R1d and R1e together form an optionally substituted C3-C6 cycloalkyl ring; R2 represents hydrogen or optionally substituted C1-C6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

Cobalt(II)-based Metalloradical Activation of 2-(Diazomethyl)pyridines for Radical Transannulation and Cyclopropanation

A new catalytic method for the denitrogenative transannulation/cyclopropanation of in-situ-generated 2-(diazomethyl)pyridines is described using a cobalt-catalyzed radical-activation mechanism. The method takes advantage of the inherent properties of a CoIII-carbene radical intermediate and is the first report of denitrogenative transannulation/cyclopropanation by a radical-activation mechanism, which is supported by various control experiments. The synthetic benefits of the metalloradical approach are showcased with a short total synthesis of (±)-monomorine.

An efficient synthetic approach towards new 5,5’-diaryl-2,2’-bipyridine-based fluorophores

An efficient approach has been developed for the synthesis of 5,5′-diaryl-2,2′-bipyridines via their 1,2,4-triazine analogues. The notable advantages of the present method are: The possibility of varying the aromatic substituents in the positions 5 and 5′ of bipyridine core and the possibility for obtaining 2,2′-bipyridines bearing a fused cyclopentene core to increase the solubility in organic solvents. These 5,5′-diaryl-2,2′-bipyridines exhibited an intense emission in a range of ca. 422–521?nm in acetonitrile solution; depending on the nature of the aromatic substituents and the presence of annulated cyclopentene fragments. Apart from that, the significant bathochromic shifts of the both absorption and emission maxima were observed in comparison with a number of previously described similar structures. In some cases the significant increasing of the fluorescence quantum yields took place.

Perfluorinated ligands induce meridional metal stereochemistry to generate M8L12, M10L15, and M12L18 prisms

Meridional (mer) coordination promotes the generation of larger and lower-symmetry prismatic metallosupramolecular structures, in contrast with the facial (fac) coordination common to smaller and higher-symmetry polyhedra. Here, we describe a general route to the selective formation of large metallosupramolecular prisms that contain exclusively mer-coordinated metal vertices. The use of 2-formylpyridine subcomponents that contain perfluorophenylene substituents at their 5-positions resulted in stereoselective formation of the iron(II) complexes from these subcomponents. Only mer vertices were observed, as opposed to the statistical fac/mer mixture otherwise generated. This mer-selective self-assembly could be used to prepare tetragonal (M8L12), pentagonal (M10L15), and hexagonal (M12L18) prisms by taking advantage of the subtle selectivities imposed by the different anilines and counterions employed. The equilibrium between the tetragonal and pentagonal prism followed a linear free-energy relationship, with the ratio between structures correlating with the Hammett σp+ parameter of the incorporated aniline. The contrasting preferences of the fluorinated and nonfluorinated ligands to generate prisms and tetrahedra, respectively, were quantified energetically, with the destabilization increasing linearly for each "incorrect ligand" incorporated into either structure.

2-indolizine Carbamoyl amine compound and its preparation and use

The invention discloses a novel 2-indolizine formylamine derivative. The general formula of the novel 2-indolizine formylamine derivative is as shown in a formula (I), wherein the definition of R is specified in the specification. In addition, the inventi

CXCR4 chemokine receptor binding comounds

The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.